The serum high-sensitive C reactive protein and homocysteine levels to evaluate the prognosis of acute ischemic stroke

dc.contributor.authorYoldas, Tahir
dc.contributor.authorGonen, Murat
dc.contributor.authorGodekmerdan, Ahmet
dc.contributor.authorIlhan, Fulya
dc.contributor.authorBayram, Ednan
dc.date.accessioned2026-08-12T17:29:53Z
dc.date.issued2007
dc.departmentFırat Üniversitesi
dc.description.abstractIschemic stroke is one of the most common causes of death worldwide and is most often caused by thrombotic processes. We investigated the changes in hsCRP and homocysteine levels, two of these risk factors, during the acute period of ischemic stroke and evaluated the relationship between these levels and the short-term prognosis. HsCRP and homocysteine levels were measured at the 2nd, 5th, and 10th days in forty patients admitted within second of an ischemic stroke. The clinical status of the patients was simultaneously evaluated with the Scandinavian stroke scale. The results were compared with 40 healthy control subjects whose age and sex were matched with the patients. The mean hsCRP levels of the patients were 9.4 +/- 7.0mg/L on the 2nd day, 11.0 +/- 7.4mg/L on the 5th day, and 9.2 +/- 7.0mg/L on the 10th day. The mean hsCRP level of the control subjects was 1.7 +/- 2.9mg/L. The mean hsCRP levels of the patients on the 2nd, 5th, and 10th days were significantly higher than the control subjects (P <.001). The patients' mean homocysteine levels were 40.6 +/- 9.6 mol/L on the 2nd day, 21.7 +/- 11.1 mol/L on the 5th day, and 20.7 +/- 9.2 mol/L on the 10th day. The mean homocysteine level of the control subjects was 11.2 +/- 1.1 mol/L. The homocysteine levels of the patients were higher than the control subjects at all times (P <.01). In conclusion, patients with stroke have a higher circulating serum hsCRP and homocysteine levels. Short-term unfavorable prognosis seems to be associated with elevated serum hsCRP levels in patients with stroke. Although serum homocysteine was found to be higher, homocysteine seems not related to prognosis.
dc.identifier.doi10.1155/2007/15929
dc.identifier.issn0962-9351
dc.identifier.issn1466-1861
dc.identifier.orcid0000-0003-4950-9142
dc.identifier.orcid0000-0002-3718-9519
dc.identifier.orcid0000-0001-7790-1358
dc.identifier.pmid17597836
dc.identifier.scopus2-s2.0-38749148798
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1155/2007/15929
dc.identifier.urihttps://hdl.handle.net/11508/55865
dc.identifier.volume2007
dc.identifier.wosWOS:000248216100001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHindawi Ltd
dc.relation.ispartofMediators of Inflammation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectPlasma Homocysteine
dc.subjectCardiovascular Risk
dc.subjectDisease
dc.subjectHyperhomocysteinemia
dc.subjectHomocyst(E)Ine
dc.subjectInterleukin-6
dc.subjectInflammation
dc.subjectAssociation
dc.subjectMarkers
dc.titleThe serum high-sensitive C reactive protein and homocysteine levels to evaluate the prognosis of acute ischemic stroke
dc.typeArticle

Dosyalar